Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 9/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24631608 | 1.00 | DRD2 (0.40) | DRD2RORCMTNR1AMTNR1BNPY5R | |
| SCHEMBL24631367 | 0.92 | DRD2 (0.40) | DRD2RORCMTNR1AMTNR1BNPY5R | |
| SCHEMBL24631549 | 0.92 | DRD2 (0.40) | DRD2RORCMTNR1AMTNR1BNPY5R | |
| SCHEMBL24631432 | 0.84 | NPY5R (0.39) | RORCNPY5RACACBACACA | |
| SCHEMBL30134737 | 0.84 | NPY5R (0.39) | RORCNPY5RACACBACACA | |
| SCHEMBL24631428 | 0.84 | NPY5R (0.39) | RORCNPY5RACACBACACA | |
| SCHEMBL24631613 | 0.81 | HTR2C (0.41) | DRD2 | |
| SCHEMBL24631618 | 0.81 | HTR2C (0.41) | DRD2 | |
| SCHEMBL24631684 | 0.80 | HTR2C (0.42) | DRD2 | |
| SCHEMBL24631614 | 0.80 | HTR2C (0.42) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4319738-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022217265-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245658-A1 | TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TAAR1, TAAR5, NPY1R | DRD2 235/4885RORC 1750/4885MTNR1A 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.